EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses
Executive Summary
The EMA is to further refocus on its core activities to help it deal with “higher than expected” staff losses due to its relocation to Amsterdam.
You may also be interested in...
Brexit: New Deadlines Kick In For Industry And ‘Reassigned’ Rapporteurs
The European Medicines Agency has announced the post-authorization procedures that the newly reassigned (co-)rapporteurs must start handling as of this month.
Brexit Bites EMA: Huge Staff Losses Freeze Many Projects
The EMA is halting its cherished transparency initiative on study data as it reckons with the fact that many of its employees will not be relocating to its new headquarters in Amsterdam. International collaboration, guidelines development and revision, and the agency's involvement in stakeholder meetings will all be cut back.
EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit
The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.